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Optimal management of the condition of patients
with small abdominal aortic aneurysms (AAAs)
remains unresolved. Proponents of early surgery
believe that this treatment allows for an operation
when the patients are younger and healthier, thereby
minimizing operative mortality rates and eliminating
the potential for future rupture. Proponents of sur-
veillance (or watchful waiting) believe that ultra-
sound follow-up with a possible future operation at a
larger diameter threshold can avoid an operation in
many patients, with minimal risk of rupture and an
acceptable increase in operative mortality rates for
patients who undergo later repair. From the patients’
perspective, the fear of rupture and likely death must
be weighed against the upfront risk of operative
death and complications.
The recently published United Kingdom small
aneurysm trial is the first randomized controlled trial
to address this issue.1 In the United States, a similar
randomized study, the aneurysm detection and man-
agement trial is still ongoing.2 In the UK trial, 527
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(0.14 QALYs) at a small incremental cost of $1510. Thus, despite a small survival ben-
efit, early surgery appeared cost-effective ($10,800/QALY). The small cost differential
resulted from the large proportion of patients who underwent surveillance, who even-
tually underwent AAA repair, and therefore incurred the cost of the surgical procedures.
The survival advantage and cost-effectiveness of early operation increased with lower
operative mortality, younger age, and larger AAA diameter.
Conclusion: Despite the negative conclusions of the UK trial, early surgery may be cost-
effective for patients with small AAAs, particularly younger patients (<72 years of age)
with larger AAAs (≥4.5 cm). Because the gains in life expectancy are relatively small,
however, clinical decision making should be strongly guided by patient preferences. 
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patients aged 60 to 76 years who had asymptomatic
AAAs (diameter, 4.0-5.5 cm) were randomized to
surveillance; 563 such patients were randomized to
early surgery. Patients in the surveillance group were
carefully followed with ultrasound diameter measure-
ments. If an AAA exceeded 5.5 cm, became tender,
expanded by more than 1 cm per year, or if iliac or
thoracic aneurysm repair was needed, elective AAA
repair was recommended. Although the all-cause
mortality rate after early operation (7.0%/yr) was less
than the surveillance group (7.4%/yr), this difference
was not statistically significant. In addition, costs in
the UK trial were higher in the early surgery group,
although this difference was small ($1700), because
61% of patients in the surveillance group eventually
underwent surgery and also incurred substantial
costs.3 With no significant survival benefit and
increased costs, early surgery did not appear cost-
effective. However, the UK trial was not powered to
detect small but potentially meaningful gains in life
expectancy that might become significant when
extended over the entire lifetime of these patients.
Furthermore, hazard ratios from subgroup analyses,
although not statistically significant, suggested a
potential benefit of early surgery for younger patients
and patients with larger AAAs.
We developed a decision analysis model to evalu-
ate the cost-effectiveness of early repair of small
AAAs compared with surveillance, based on data
from the UK trial. We further analyzed the influence
of AAA diameter and patient age on cost-effective-
ness, using subgroup analyses from these data.
Because the elective operative mortality rate for early
surgery in the UK trial (5.8%) was higher than
expected (2%),4 we also evaluated the effect of oper-
ative mortality rate on cost-effectiveness using sensi-
tivity analysis.
METHOD
Calculation of cost-effectiveness. We used a
Markov decision analytic model5,6 to simulate
expected costs and quality-adjusted survival in large
cohorts of patients with small AAAs who were treat-
ed with early surgery or surveillance. In the model,
hypothetic patients make transitions over time
between three defined health states: alive with an
intact AAA, alive after AAA repair, and dead.
Transitions between these health states occur
according to defined probabilities, all derived direct-
ly from the UK trial. Each health state is assigned a
cost and a quality adjustment (ranging from 0
[dead] to 1 [alive in perfect health]). With each
cycle of the model (6 months in our analysis),
patients accumulate both costs (in dollars) and qual-
ity-adjusted survival (in quality-adjusted life years
[QALYs]).
To enhance the comparability of cost-effective-
ness ratios across health interventions, cost-effective-
ness analyses are ideally based on lifetime simulations
of related costs and quality-adjusted survival.7 Thus,
for our baseline analysis, we used a lifetime perspec-
tive, but we also performed an analysis limited to the
first 6 years to allow direct comparison of our model
with the perspective reported in the UK trial.
The marginal cost-effectiveness of early surgery
was calculated by dividing its net cost by its net ben-
efit in comparison with the surveillance strategy. Net
costs were determined by the difference between
expected costs of early surgery and those of surveil-
lance. Similarly, net benefits reflect the number of
QALYs accrued by patients in the early surgery strat-
egy, less those accrued by patients in the surveillance
group. Therefore the marginal cost-effectiveness
represents the additional cost incurred per QALY
gained by choosing one strategy over another. Both
future costs and benefits were calculated with the use
of a 3% annual discount rate, as recommended by the
United States Public Health Service, so that future
costs and benefits will have less impact.7 We devel-
oped the decision model using the software program
DATA 3.0 (TreeAge Software Inc, Williamstown,
Mass).
Transition probabilities. For the surveillance
group, the transition probabilities between health
states were derived directly from annual mortality
rates reported in the UK trial. Table I summarizes
mortality rates for all patients and those rates for sub-
groups according to age (60-66, 67-71, and 72-76
yrs) and initial AAA diameter (4.0-4.4, 4.5-4.8, and
4.9-5.5 cm). Annual mortality rates were converted
to 6-month transition probabilities for the model
with the use of the exponential transformation, P = 1
– exp (–r × t), where P is the probability, r is the mor-
tality rate, and t is the cycle-length (0.5 yrs).
For transition probabilities in the early surgery
group, we also used the annual mortality rates
reported from the UK trial, but we separated the risk
of operative death (at time zero) from later annual
mortality rates to allow specific analysis of operative
mortality rate. To determine annual mortality rates
exclusive of operative mortality rate for the early
operation group (Table I), we first calculated the 6-
year overall probability of death using mortality rates
from the UK trial with the aforementioned formula.
We then subtracted the probability of initial opera-
tive mortality from the overall 6-year mortality rate
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and recalculated the average annual mortality rate
using the formula, r = - ln (1 - P)/6 years, where P
is the cumulative probability of mortality, and r is
the mortality rate. Finally, annual mortality rates
were converted to 6-month transition probabilities,
as described earlier. An example of these calculations
is shown in the Appendix.
Information about events after 6 years in the UK
trial is not available. Although mortality rates in the
UK trial were higher for patients who underwent
surveillance (7.4%/yr) than for patients who under-
went early operation (7.0%/yr) in our model, we
assumed that mortality rates for the two groups
would become equal after 6 years. This may bias our
model against early surgery. For all time points after
6 years, mortality rates were set according to age,
sex, and race adjusted mortality tables.8 An addi-
tional 3% mortality per year was added to the age-,
sex-, and race-adjusted rates to reflect the excess
comorbidity associated with AAA disease.9-11
Reflecting the operative mortality observed in
the UK trial, we assumed an operative mortality rate
of 5.8% for our baseline analysis of all patient sub-
groups. To test the potential effect of different oper-
ative mortality rates on the cost-effectiveness of early
operation, we used a sensitivity analysis over a plau-
sible range (0%-10%). For each simulation, we
applied the same change in operative mortality rate
for patients in both the early operation group and
those patients in the surveillance group who subse-
quently underwent operation (maintains the same
absolute difference in operative mortality observed
in the UK trial for early operation [5.8%] and sur-
veillance [7.2%]). To adjust overall annual mortality
rates in the surveillance group for potentially differ-
ent operative mortality risk, we estimated the pro-
portion of patients in the surveillance group who
underwent operation in each subsequent cycle of the
model. This proportion was derived from life-table
data for this event rate as presented in the UK trial
(in which 75% of the patients who underwent non-
censored surveillance had undergone surgical proce-
dures by 5 years), with the use of methods analo-
gous to those described earlier for patients who
underwent early operation.
Costs and quality of life adjustment. Direct
health care costs related to AAA surveillance and
repair were also obtained from the UK trial.3 Costs
examined in this trial reflected resource-based costs
of ultrasound examinations, office visits, and surgery
(elective and emergent) for patients in the early
surgery and surveillance groups. In the UK trial, the
cost of surgery was based on a prior study of 87
patients who underwent elective AAA repair at two
hospitals in Scotland.12 Costs associated with surveil-
lance were also estimated by the UK trialists from
previously published data.3 We converted costs from
the UK trial in 1996 to 1997 British pounds to 1996
to 1997 US dollars (conversion rate, 1.600). In our
model, all early surgery costs ($8000/patient) were
applied at time zero. Total predicted costs for the
surveillance group ($6664/patient) were annualized
($1449/yr, based on the mean follow-up of 4.6 years
in the trial) and applied to the surviving cohort mem-
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Table I.  Average annual mortality rates for patients who underwent surveillance and who underwent early
operation in the UK small aneurysm trial
Annual mortality rate (%/yr)
Surveillance* Early surgery (%)
Exclusive of initial 5.8% 
operative  mortality 
Overall* rate†
Overall 7.4 7.0 5.6
Subgroups
Initial AAA diameter
4.0-4.4 cm 6.5 7.4 6.0
4.5-4.8 cm 6.8 6.3 4.9
4.9-5.5 cm 9.2 7.4 6.0
Initial patient age
60-66 y 5.8 4.7 4.0
67-71 y 8.9 6.8 5.4
72-76 y 7.6 9.5 7.9
*As reported in the UK trial.
†Rate used in our analysis for annual mortality, after excluding initial operative mortality that was analyzed separately.
bers during each cycle of the model. Because only a
small percentage of survivors at 6 years were still
undergoing surveillance, costs in our model after 6
years were set to zero. This introduced a slight bias
against early surgery.
To enhance the comparability of our cost-effec-
tiveness estimates with those of other health interven-
tions, we used quality of life weights to estimate the
benefit (or harm) of early surgery in terms of QALYs.
As measured by functional health status scores
(Medical Outcomes Study short-form patients’ health
survey [SF-36]13,14), overall health-related quality of
life did not differ between the early operation and sur-
veillance groups in the UK trial.3 Thus operative com-
plications other than death did not impact significant-
ly on the quality of life of the early surgery group rel-
ative to the surveillance group. However, relatively low
functional status scores observed in both groups
reflected both advanced age and comorbidity that is
typical of patients with AAAs. In our model, we
assigned a quality-adjustment weight (utility 0.86 for
both early operation and surveillance groups) reflective
of this chronic disease state.15
RESULTS
Based on a 5.8% elective operative mortality
rate, our model predicted a life expectancy of 7.15
QALYs for patients who underwent early surgery and
7.01 QALYs for patients who underwent surveil-
lance, resulting in a net benefit of 0.14 QALYs (51
days) for early surgery. Sensitivity analysis showed
that this benefit of early surgery was inversely related
to elective operative mortality and disappeared com-
pletely as operative mortality approached 10% (Fig
1). Lifetime projected costs in the early surgery
cohort were $8000 compared with $6490 in the sur-
veillance group. Based on the small additional cost of
$1510 for early surgery and a net benefit of 0.14
QALYs, the marginal cost-effectiveness ratio was
$10,800 per QALY for early operation, which would
be considered “cost-effective.”
If one adopted a 6-year instead of a lifetime per-
spective, early surgery actually resulted in net harm,
with a reduced survival benefit of 0.04 QALYs (15
days). After only 6 years, the late benefit of early oper-
ation observed in the UK trial had not yet overcome
the initial harm of elective operative mortality rates.
With higher cost and net harm, early surgery was dom-
inated by surveillance when analyzed from this 6-year
perspective. This corresponds with the conclusion of
the UK trial but ignores the eventual benefit of early
surgery, which becomes meaningful in our model over
the life of these patients (Table II). Sensitivity analysis
of operative mortality rates over the range of 0% to
10% revealed dramatic differences between the lifetime
and 6-year simulations (Fig 2). With the use of only a
6-year perspective, it appears that an elective operative
mortality rate of less than 3% must be achieved for
early surgery to be considered cost-effective. However,
when a lifetime perspective is applied, early surgery
appears cost-effective until the elective surgery mortal-
ity rate approaches 10% (Fig 2).
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Fig 1. The predicted effect of elective operative mortality
rates on the net quality-adjusted survival benefit of early
surgery compared with surveillance.
Fig 2. The effect of elective operative mortality rates on
the cost-effectiveness of early surgery versus surveillance,
with the use of both standard lifetime projections and a
more limited 6-year perspective.
In subgroup analysis by AAA diameter (Table
III), our model predicts a net harm of 0.27 QALYs
for patients with AAA diameters 4.0 to 4.4 cm who
undergo early surgery. For AAA diameters 4.5 to 4.8
cm, however, a net benefit of 0.18 QALYs would be
gained at a net cost of $1410. For the largest AAA
diameters (4.9-5.5 cm), the net benefit is even more
pronounced at 0.54 QALYs. Marginal cost-effec-
tiveness ratios for these larger AAA diameters are
$7800 and $3400 per QALY, respectively, well
within the definition of cost-effective. Thus our
decision model suggests that repair of AAAs that are
4.5 cm or more in diameter is cost-effective.
In subgroup analysis by age (Table III), our
model predicts a net harm from early surgery in the
oldest patients (72-76 years of age). Through the
selection of early surgery, 0.43 QALYs would be lost
in these patients when compared with surveillance
and possible later surgery. For the younger age
groups analyzed in the UK trial (60-66 and 67-71
years of age), early operation yields a net benefit of
0.20 and 0.63 QALYs, respectively, with favorable
marginal cost-effectiveness ratios of $6100 and
$2800 per QALY. Thus our decision model suggests
that repair of small AAAs in patients who are less
than 72 years of age is cost-effective.
Varying operative mortality rates in these sub-
groups over a clinically relevant range (0%-10%; sensi-
tivity analysis) had minimal effect in the lifetime simu-
lation. Early operation in patients with larger AAA
diameters (4.5-5.5 cm) and younger age (60-71 yrs)
yielded marginal cost-effectiveness ratios below
$50,000 across the range of operative mortality rates
tested. Interestingly, patients with smaller AAA diame-
ters (4.0-4.5 cm) and older patients (72-76 yrs) did
not benefit from early surgery, even at 0% elective
operative mortality. In our analysis, however, patients
in each AAA diameter subgroup included all ages (60-
76 yrs); each age subgroup included all AAA diameters
(4.0-5.5 cm), based on the published UK trial results.
Sensitivity analysis of the cost of early surgery
revealed that the marginal cost-effectiveness ratio
remains below $50,000 per QALY until the cost of
early surgery is increased above $14,000, an unrealis-
tic increase of 75%. Sensitivity analysis of all other vari-
ables across plausible ranges showed that no other
variable affected the outcome of our baseline analysis.
DISCUSSION
The upper limit for a definition of cost-effective
healthcare usually varies between $20,000 and
$100,000 per QALY.16 Almost all medical therapies
with marginal cost-effectiveness ratios of less than
$50,000 per QALY are considered cost-effective.17
Some widely accepted interventions with ratios of
$50,000 to $100,000 per QALY are also considered
cost-effective, such as hemodialysis for chronic renal
failure ($53,000 per QALY).18 Few would consider
ratios above $100,000 per QALY to be cost-effec-
tive, although some such therapies are widely prac-
ticed, such as universal precautions for HIV preven-
tion ($770,000 per QALY).19
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Table III. Lifetime analysis of cost-effectiveness
(C-E) of early repair relative to surveillance*
Net benefit Net cost of Marginal 
of surgery surgery C-E ratio 
(QALYs) ($US) ($US/QALY)
Initial AAA 
diameter (cm)
4.0-4.4 –0.27 1350 Dominated†
4.5-4.8 0.18 1410 7800
4.9-5.5 0.54 1820 3400
Initial patient 
age (y)
60-66 0.20 1230 6100
67-71 0.63 1770 2800
72-76 –0.43 1550 Dominated†
*The assumed operative mortality rate for early surgery in all sub-
groups, 5.8%.
†Early surgery is both more expensive and less efficacious.
Table II. Costs, benefits, and marginal cost-effectiveness (C-E) ratios of early surgery relative to surveil-
lance*
Benefit Net benefit Cost Net cost Marginal C-E ratio 
Analysis Strategy (QALE) (QALE) ($US) ($US) ($US/QALYs)
Lifetime Early operation 7.15 8000
Surveillance 7.01 0.14 6490 1510 10,800
6-yr Early operation 3.84 8000
Surveillance 3.88 -0.04 6490 1510 Dominated†
*Operative mortality rate for patients who underwent early operation, 5.8%.
†Early surgery is both more expensive and less efficacious.
QALE, Quality adjusted life expectancy.
Given this perspective, it would appear from our
model that early surgery for small AAAs is cost-effec-
tive when compared with ultrasound scanning sur-
veillance and subsequent operation at a larger diam-
eter threshold. The marginal cost-effectiveness ratio
was only $10,800 per QALY for early operation
compared with surveillance, based on results from
the UK small aneurysm trial. However, it is impor-
tant to understand the basis for this calculation and
its implication for decision making. The net benefit
of early surgery as predicted by our model was small
(only 0.14 QALYs) over the lifetime of these
patients. Thus favorable cost-effectiveness ratios
were generated only because the net cost of early
surgery was also very small ($1510). Costs for the
surveillance group of the UK trial were nearly as
high as the early surgery group because of the large
proportion of patients who underwent surveillance
and who eventually underwent AAA repair (77% in
our lifetime model) and the costs of ultrasound
imaging and follow-up. In terms of benefit, the ini-
tial harm from operative mortality in the patients
who underwent early surgery was eventually over-
come by the small but present rupture risk (1%/yr)
combined with an increased operative risk (7.2% vs
5.8%) for those patients who eventually underwent
AAA repair in the surveillance group. The survival
curves for early surgery and surveillance in our
model and in the UK trial crossed at 3 years, reflect-
ing the initial harm but later benefit of early surgery
(Fig 3). The difference between these survival curves
represents the net benefit or harm of each strategy.
A net benefit for early surgery was not reached by 6
years but was reached when projected over the life-
time of these patients. This effect is illustrated in Fig
3 and explains the difference in the conclusion of
our decision model and the UK trial, where a 6-year
perspective was used.
As expected, the net benefit of early surgery
declined as operative mortality rates increased (Fig
1). The fact that operative mortality did not have a
more pronounced effect on cost-effectiveness is at
first surprising. However, it is explained by the fact
that patients in the surveillance group in our model
were subjected to the same relative change in elective
operative mortality when they subsequently required
surgery. Given that 77% of the patients who were
undergoing surveillance eventually underwent
surgery in the lifetime projection, it is clear that any
change in operative mortality rate is reflected almost
equally in both groups. If a lower elective operative
mortality rate is achieved for patients who undergo
early surgery through careful patient selection or per-
formance of AAA repair only in centers of excellence,
it is likely that this could also be obtained subse-
quently for patients in a surveillance program. This is
plausible because most patients who undergo surveil-
lance and who eventually undergo AAA repair do so
within several years, thereby minimizing the effect of
comorbid disease progression. The lack of major
impact of operative mortality rates on cost-effective-
ness in our model does not negate the benefit of low
operative mortality rates but rather demonstrates that
this is not the key factor for selecting early surgery
over surveillance.
Similarly, sensitivity analysis showed that varying
the cost of surgery over a plausible range had no
effect on the results. This is also explained by the fact
that most of the patients who underwent surveil-
lance eventually underwent surgery, thereby mini-
mizing any potential financial gain of choosing the
surveillance strategy.
Through analysis of subgroups in our study, we
examined the effect of AAA diameter and patient age
on cost-effectiveness. Patients with larger AAA diam-
eters (4.5-5.5 cm) seemed to benefit from early
repair although those with AAAs that were less than
4.5 cm in diameter did not. This diameter threshold is
similar to those from previous decision analyses.20-22
In a recent clinical study by Brown et al,23 fit patients
were selected for operation when AAA diameter
reached 5.0 cm. In that study the authors noted an
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Fig 3. The projected survival rate based on decision analy-
sis modeling for early surgery versus surveillance, based on
data from the UK small aneurysm trial. Area between the
curves represents the net benefit (or harm) of each strategy.
increased expansion rate at AAA diameters above 4.5
cm and several AAA ruptures at or slightly above 5
cm. Therefore they recommended surgery for fit
patients when AAA diameter reaches 4.5 cm.
In our model, younger patients (60-71 yrs)
appeared to benefit from early AAA repair although
older patients (72-76 yrs) did not. Again, this con-
curs with prior decision analyses. With the use of
recently published estimates of rupture risk24 and
operative mortality rates from the Medicare database
in 1995 Finlayson et al,22 using Markov modeling,
found that the optimal size threshold for open AAA
repair was age dependent, ranging from 4.6 cm at
age 60 years to 5.1 cm at age 80 years.
In our model, we applied the operative mortali-
ty rate (5.8%) of early surgery equally to all age
groups, because a subgroup analysis has not yet been
published for the UK trial. It is more likely that the
operative mortality rate in the UK trial was age
dependent, as was the case in the Medicare database
where the operative mortality rate was 5.2% in the
United States Medicare population in 1995 but
ranged from 3% in patients aged 65 to 69 years to
10% in patients over age 80 years.22 This introduces
a bias against early surgery for the younger patients
that may have contributed to the apparently reduced
benefit of early surgery for patients aged 60 to 66
years relative to those aged 67 to 71 years in our
model (Table III). In older patients, this assumption
of equal operative mortality rates would bias in favor
of early surgery. However, it did not affect the con-
clusion of our model because early surgery was dom-
inated by surveillance in the older age group.
Our model was unable to evaluate the interac-
tion of age and AAA diameter. It is likely that the
optimal threshold diameter for elective AAA repair
would be lower for younger patients and higher for
older patients, as was demonstrated previously.22
Therefore the subgroup of older patients (72-76 yrs)
with the largest AAAs (4.9-5.5 cm) might be expect-
ed to benefit from early surgery. Similarly, patients
with the smallest AAAs (4.0-4.4 cm) who were
younger might benefit as well.
Our lifetime simulation is based on the assump-
tion that mortality rates are equal in the early
surgery and surveillance groups beyond 6 years. This
is not unreasonable because approximately 85% of
survivors in the surveillance group in the UK trial
had undergone AAA repair by 6 years. The remain-
ing fraction of the patients who underwent surveil-
lance with intact AAAs were still susceptible to the
1% per year rupture risk and the increased operative
mortality rate (1.4% higher than early operation) for
those who would eventually undergo repair. Thus it
is likely that this fraction of the patients who under-
went surveillance would actually be exposed to a
higher annual mortality risk after 6 years than those
patients who had already undergone AAA repair in
both groups. For this reason, our assumption of
equal mortality rates in both groups after 6 years
may bias the model against early surgery. Similarly,
the patients who underwent surveillance and who
had not yet undergone repair would continue to
incur costs associated with surveillance after 6 years.
By setting costs to zero after 6 years we have intro-
duced a further bias against early surgery in our
model.
Overall, our results do not conflict with, but
rather extend, the results of the UK small aneurysm
trial using a lifetime simulation. Unfortunately, the
UK trial could not be powered to detect small dif-
ferences in mortality rates, which we have shown by
decision analysis to be important from a lifetime per-
spective. Given that these differences were not sta-
tistically significant in the UK trial, we cannot be
sure of the accuracy of our conclusion. However, if
the elective mortality rate in the UK trial had been
as low as predicted when the trial was designed (2%),
we believe that a significant benefit of early surgery
would have been proved. This was true when we
analyzed the 6-year perspective of the UK trial. Even
without this low operative mortality rate, however,
our decision model demonstrates that small differ-
ences in survival rates, if truly representative of the
patient population, can become important when
projected over the lifetime of these patients.
How should these results influence clinical prac-
tice? The survival advantage seen with early surgery
increased at larger AAA diameters and lower opera-
tive risk but decreased at older age and higher oper-
ative risk. Because over 75% of the patients who
undergo surveillance from all age groups predictably
undergo repair as AAA expansion occurs, it is likely
that younger patients with longer life expectancy
would be even more likely to undergo repair. Thus,
for younger patients, it is usually a question of
“when” rather than “whether” to repair small AAAs.
From a societal perspective, early surgery appears
cost-effective because of the minimal cost differen-
tial despite the small survival benefit. Translating this
into recommendations for individual patients, how-
ever, is difficult. Given the small overall survival
advantage predicted by our model, it would seem
prudent to emphasize patient preference in choosing
between the up-front risk of operative death versus
the small risk of rupture and increased future opera-
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tive risk in a careful surveillance program. In conclu-
sion, using a lifetime simulation with data from the
UK small aneurysm trial, we have found that early
surgery was cost-effective, with a marginal cost-
effectiveness ratio of only $10,000/QALY com-
pared with surveillance. This was true largely
because most patients who underwent surveillance
ultimately underwent surgical repair so that the cost
difference between the two strategies was minimal.
Patients younger than age 72 years and those
patients with AAA diameters of 4.5 cm or more are
particularly likely to derive benefit and demonstrate
cost-effectiveness with early AAA repair.
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Appendix. Illustration of methods used to recalcu-
late annual mortality rates for patients who under-
went early surgery after operative mortality rates
have been withdrawn
Step Task Formula Example*
1 Convert annual p = 1 – e–rt 1 – e–0.070·6 =
mortality rate (r) 0.343
to 6-y cumulative 
probability (p) of 
death (t = time)
2 Subtract operative p1 = p – m 0.343 – 0.058 =
mortality rate (m) 0.285
from 6-y cumula-
tive probability (p) 
of death
3 Use “adjusted” r1 = –ln(1 – 0.285)/
cumulative proba- – ln(1 – p1)/t 6 = 0.056/y
bility (p1) of death 
to recalculate 
annual mortality 
rate (r1)
*Early surgery mortality rate, 0.07/y; 6-y perspective; operative
mortality rate, 5.8%.
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DISCUSSION
Dr K. Craig Kent (New York, NY). The United
Kingdom small aneurysm trial may have produced the
long-awaited answer to a question that has perplexed vas-
cular surgeons for many years: Should small AAAs, defined
in this trial as 4.0 to 5.5 cm in diameter, be prophylacti-
cally repaired? The authors of the UK study would like us
to believe the answer is no.
The impact of the UK study on the thinking and the
behavior of the medical profession is potentially substan-
tial. Some of my own referring physicians now question
my decision to repair 5-cm aneurysms even in younger
patients. Because of its potential impact on our practices,
the UK study deserves close scrutiny. I am thankful to Drs
Schermerhorn and Cronenwett and their colleagues at
Dartmouth for placing this data in perspective.
With decision analytic techniques and the numeric
data from the small aneurysm trial, the Dartmouth group
has shown that the repair of 4.0- to 5.5-cm AAAs may be
cost-effective. Although not statistically significant, there
was in the UK study a small reduction in the yearly mor-
tality rate in those patients who were treated with early
operation. This reduction, if summed over the lifetime of
patients, provided a significant improvement in overall
survival. Moreover, the additional cost assigned to the
cohort treated with early operation was not as great as one
might expect because almost 75% of the patients in the
surveillance program eventually incurred the cost and
morbidity associated with aneurysm repair.
The potential weakness in this analysis is the assump-
tion made by the authors that early operation in fact does
reduce mortality rates. Although early operation did pro-
duce a numeric reduction in deaths, approximately 0.4%
per year, this reduction was not statistically significant.
Without the strength of a statistical difference, it is per-
haps unfair for the authors to introduce two different
numbers for mortality rates for patients undergoing
surgery and surveillance into their decision analytic model.
If one assumes that the yearly mortality rates for early
operation and surveillance are identical, which they are
from a statistical standpoint; then, in the base case analy-
sis, there will be no cost advantage to surgery.
With this as my only reservation, the importance of
this study resides in the sensitivity analyses and the
authors’ analyses of the subgroups. The perioperative
mortality rate for aneurysm repair in the UK trial was
5.8%, a number that is surprisingly high and greater than
was anticipated by the authors when they designed this
trial. Mortality rates for aneurysm repair of less than 2%
have been reported by many individual centers, and large
multicenter trials (such as the Canadian study) have
revealed mortality rates of less than 5%. Presumably,
lower operative mortality rates will have a beneficial
effect on the cost-effectiveness of early operation in your
analysis. 
In sensitivity analyses, the authors have also found that
early repair of aneurysms is cost-effective in younger
patients and also in those patients who have aneurysms
that are greater than 4.5 cm in diameter. 
It appears from your analysis that only a 0.4% reduc-
tion in a yearly mortality rate is required to make surgery
cost-effective. Does this mean that centers that can achieve
mortality rates that are low for these patients should be
aggressive in recommending early operation and not sur-
veillance? 
At Dartmouth, do you routinely consider surgery in
young otherwise healthy patients with aneurysms less than
4.5 cm in diameter? Given that you individualize your
patients, what is your broad cutoff for size? 
Is there any credence to the often used statement, it is
better to fix an aneurysm when a patient is young before
other comorbidities develop? 
Where do aortic endografts fit into your analysis? Do
they increase or decrease the cost-effectiveness of early
operation? 
The Dartmouth group has provided us with a neces-
sary critical evaluation of the UK small aneurysm trial. The
take-home message in my mind is that a uniform policy of
surveillance is not appropriate in all patients with small
aneurysms. Alternatively, it is cost-effective and, more
importantly, medically appropriate for surgeons who can
achieve low mortality rates to repair small aneurysms, par-
ticularly in younger patients. I personally will continue to
maintain an aggressive policy towards treating these
patients, and I thank the authors for their demonstration
of the sensibility of such an approach. 
Dr Cronenwett. You are correct that we did choose to
model a statistically insignificant small difference in annu-
al mortality rates between the two groups in the UK trial.
But, in fact, the purpose of our study was to show that
these very small differences in annual mortality rates,
when played out over the entire lifetime of a patient, can
in fact be very substantial. It is clearly true that our results
are only as accurate as the study, but I think the point here
is to show that the UK trial has not proved that this early
surgical intervention is not cost-effective. We may not
today have proved that it is cost-effective. In fact, the mes-
sage here, I think, in our presentation, is that when there
are such small differences in cost and benefit between two
strategies that this really does boil down to an individual
patient decision. Obviously such factors as larger
aneurysm size and patients with longer life expectancies
would be expected to add a positive benefit for early oper-
ation. The UK study, if you will remember, concluded that
early operation should not be performed for any of these
patients with smaller aneurysms, and I think our message
today is not to throw the baby out with the bath water. 
To answer your specific questions, it is important to
realize that what we are modeling here are annual mortal-
ity rates where there was a difference of 0.4%. That does
not equate to initial operative mortality rate. In fact, if the
late mortality rates of early operation and surveillance are
identical, one has to have a quite low initial operative mor-
tality to show benefit. 
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In terms of a threshold size for us, we have shown in
other decision models that, for a patient of 60 years old,
we think the ideal threshold is around 4.6 cm. Obviously,
that increases with age. So this is the advice that we give
to very young patients, which often boils down to a ques-
tion of when, rather than whether, they want the small
aneurysm repaired. 
Finally, how do endografts influence this? Obviously, if
you have a 5.8% operative mortality rate with elective
repair, endovascular grafts with, in general, a much lower
operative mortality rate, will certainly improve your results.
For a perspective, however, based on the Medicare data in
the entire United States in 1995, the elective mortality rate
for aneurysm repair was 3% for patients who were aged 65
to 69 years and 4% for patients aged 70 to 74 years or the
entire age spectrum covered by the UK trial.
Dr Roger N. Baird (Bristol, England). I was one of the
participants in that small aneurysm study. I think it is a
very important study, as has been said, and it was present-
ed at our National Vascular Surgical Society a few months
ago. It was published in the Lancet, and it has been
reviewed by editorials appearing in the European Journal
of Vascular Surgery. So it is an important study, and it is
good that it is having an airing here. 
There are one or two issues that arise. The focus in the
paper that we have just heard has been very much on the
operative mortality rates. I think it is worth considering
the number of years in which this study was in its genesis
and its execution, because there have been a lot of changes
in the years that have passed since the study was institut-
ed. The changes, as you have mentioned include stenting
and a lot more screening. 
However, what I would like to ask you about is your
view from a 1999 perspective on what you would expect
the operative mortality rate to be. Because it is our expe-
rience that the impact of stenting has been that the oper-
ative mortality rate for open repair has drifted upwards in
recent years and that the 2% that the planners of this study
used is perhaps not the case. Maybe you could give us an
insight into your own institution to see whether you
noticed any trends along these lines. 
I think the message that we would like to leave is that
this analysis is an analysis of part of the study, and the
study should be viewed in its entirety. The very small rup-
ture rate for these small aneurysms is something that we all
have to consider, I think, and we hope that perhaps the
discussion will be enlarged to some of the other aspects. I
am sorry that I do not have the methods of your study at
hand, but some of the figures you quoted on operative
costs and cost per QALYs would need to be examined in
rather closer detail to see whether they were consistent
with the United Kingdom way of practicing these things.
Dr Cronenwett. I think that no one should misinter-
pret our remarks in terms of the importance of the UK
trial, and I think that we have all learned from that trial
that the onus of responsibility is now on any surgeon who
recommends the repair of a small aneurysm to ensure, in
fact, that a low operative mortality rate is achieved and to
recognize that, if that rate is as high as 5.8%, there is very
little benefit, albeit with very little net cost difference, in
making that decision. 
In terms of that, I think it is clear that we can do more
effective screening to select patients who would be expect-
ed to have a low operative mortality rate in our individual
practice, much more so than could ever be achieved in a
widespread study of this type. It is not surprising that, in a
multicenter trial, the operative mortality rate turns out to
be somewhat higher than the best that we can achieve
when we apply all of our insights into individual patients.
Our cost-effectiveness analysis does correctly rely on data
from the UK trial, including costs from the UK trial, and
I hope that the subsequent analysis of our article will show
that they are accurate.
Dr Dhiraj M. Shah (Albany, NY). Did you analyze in
terms of various subsets of the group of patients? As I
recall from the presentation at the American Surgical
Association meeting, patients with hypertension or chron-
ic obstructive pulmonary disease or female patients have a
higher rate of rupture. Does it make any difference for
cost-effectiveness of the survival rates for this group of
patients?
Dr Cronenwett. Those data were just presented and
certainly not published, and we have not had access to it
to even begin to try modeling it. I think that it is clear that
any factors that increase rupture risk in an individual
patient will improve the cost-effectiveness of the early
operation strategy and vice versa, but we could not include
those details in this model.
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